why choose us

First received: June 19, 2023

Clinical Trial: Study of the Plasmodium Vivax Transmission-blocking Vaccine Pvs230D1-EPA/Matrix-M to Assess Safety, Immunogenicity, and Transmission-blocking Activity in Healthy Malaria-naive Adults

Study Status: Completed

Recruit Status: RECRUITING

Condition: Malaria

Study Type: INTERVENTIONAL


Official Title: Phase 1 Dose Escalation Study of The Plasmodium Vivax Transmission-Blocking Vaccine Pvs230D1-EPA/Matrix-M to Assess Safety, Immunogenicity, and Transmission-Blocking Activity in Healthy Malaria-N

Brief Summary: Background:Malaria is a disease carried by mosquitoes in tropical countries around the world.It can cause symptoms like fever, body aches, and weakness.More than half a million people worldwide died of malaria in 2021, mostly children.Researchers want to find ways to prevent the spread of this disease.Objective:To test the effects of a new malaria vaccine.(Volunteers will not be exposed to malaria.)Eligibility:Healthy adults aged 18 to 50 years.Design:Volunteers will be screened.They will have a physical exam with…

Read more